Direct vasodilators (hydralazine, minoxidil)

Medicines that lower blood pressure by relaxing the muscle in blood vessel walls. The US label read for hydralazine lists essential hypertension. The label read for minoxidil limits its use to high blood pressure that is symptomatic or damaging organs and that is not manageable with maximum doses of a diuretic plus two other blood pressure medicines, and it carries a boxed warning about serious adverse effects.

Also called Direct vasodilators · Arteriolar vasodilator

  • Drug
  • In this atlas

Overview

Technical summary

Class page. MeSH descriptor D014665 (Vasodilator Agents, last updated 2020-05-27) is a broad match, because it covers every medicine used to dilate blood vessels and not only these two. Two US labels were read: hydralazine hydrochloride tablets (application ANDA086242, effective 2025-12-10 in openFDA) and minoxidil tablets (application ANDA072708, effective 2026-01-21 in openFDA; established pharmacologic class Arteriolar Vasodilator). Both are generic labels, not the original brand. The hydralazine label says its mechanism is not fully understood. A separate claim records the minoxidil boxed warning. The label texts read state no age range for their uses. This page gives no dose, no trial result and no guideline statement. Medicines of the group that have their own pages are filed under it.

Drugs in this class

1 drug in this atlas is filed under Direct vasodilators (hydralazine, minoxidil), with the registry trials and FDA regulatory decisions this atlas holds for each. With Direct vasodilators (hydralazine, minoxidil) itself, the class has 0 distinct trials and 0 distinct FDA decisions; a trial or decision that two of them share counts once there.

About this drug

Level
Class
Mechanism
The hydralazine label says the precise mechanism is not fully understood and that it lowers blood pressure through a peripheral vasodilating effect, a direct relaxation of vascular smooth muscle. The minoxidil label calls minoxidil a direct acting peripheral vasodilator.

Classification codes

  • MeSH MeSH linked-data descriptor record fetched on 2026-11-09, lastUpdated 2020-05-27; the record states no yearly MeSH release D014665 Vasodilator Agents

Claims and evidence

Context People treated with minoxidil tablets for hypertension, as described in the boxed warning of a US label

Recipient
Recipient not specified
Population
Patients treated with minoxidil tablets, as the boxed warning of the label describes the risk.
Care setting
Prescription medicine, as described in the US label
Geography
United States (US drug label)
Life stage
Not stated in the passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
Excluded
None stated
  • Safety Evidence stage not applicable Certainty not assessed

    The label of minoxidil tablets (AvKARE, application ANDA072708; the version dated 2026-01-21 in openFDA) carries a boxed warning. It says the tablets contain a powerful antihypertensive agent that may produce serious adverse effects, and that minoxidil can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated.

    Applies to Recipient not specified People treated with minoxidil tablets for hypertension, as described in the boxed warning of a US label

    Certainty method
    Not assessed
    Limitations
    This claim records two statements of the label's boxed warning only. The boxed warning also lists other effects and steps for managing treatment; they are not repeated here. The label read is a generic label, not the original brand, and states no age range. Other warnings, contraindications, interactions and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0]
      How it applies
      Serious adverse effects, pericardial effusion and angina.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260121.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context People with hypertension, for minoxidil only hypertension that is symptomatic or damaging organs and not manageable with maximum doses of a diuretic plus two other drugs, as described in two US labels

Recipient
Recipient not specified
Population
Patients described in the indications sections of the two labels: patients with essential hypertension (hydralazine), and patients with hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs (minoxidil).
Care setting
Prescription medicine, as described in the US labels
Geography
United States (US drug labels)
Life stage
Not stated in the passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Essential hypertension (hydralazine label)
  • Hypertension that is symptomatic or associated with target organ damage and not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs (minoxidil label)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    Two US generic labels were read. The label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct, and says the medicine apparently lowers blood pressure through a peripheral vasodilating effect, a direct relaxation of vascular smooth muscle. The label of minoxidil tablets (AvKARE, application ANDA072708; the version dated 2026-01-21 in openFDA) calls the medicine an antihypertensive peripheral vasodilator, and says that because of the potential for serious adverse effects it is indicated only for hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. MeSH describes vasodilator agents as drugs used to cause dilation of the blood vessels.

    Applies to Recipient not specified People with hypertension, for minoxidil only hypertension that is symptomatic or damaging organs and not manageable with maximum doses of a diuretic plus two other drugs, as described in two US labels

    Certainty method
    Not assessed
    Limitations
    This claim records what two US generic labels say. It is not a finding about how well either medicine works, and no trial result is recorded for it in this atlas. Neither label is the original brand. The labels read state no age range. The minoxidil boxed warning is recorded in a separate claim. Other warnings, contraindications, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (7)
    1. Supports openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE
      How it applies
      Hydralazine: essential hypertension.
      Retrieved
      Source effective date
      2025-12-10
      Source state
      Current
      Version fingerprint
      4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].clinical_pharmacology[0], CLINICAL PHARMACOLOGY
      How it applies
      Hydralazine: peripheral vasodilating effect.
      Retrieved
      Source effective date
      2025-12-10
      Source state
      Current
      Version fingerprint
      4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for hydralazine hydrochloride tablets, Chartwell RX, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 0c7f9bd0-6c0a-4521-b77a-3582faa96874 (manufacturer Chartwell RX, LLC, application ANDA086242), returned on 2026-11-09. The label text is dated 2025-12-10 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20251210.
      Retrieved
      Source effective date
      2025-12-10
      Source state
      Current
      Version fingerprint
      4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE
      How it applies
      Minoxidil: limited use in hypertension.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].description[0], DESCRIPTION
      How it applies
      Minoxidil: antihypertensive peripheral vasodilator.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Background openFDA drug label record for minoxidil tablets, AvKARE label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 02d7399f-94cc-f718-f214-587301edd138 (manufacturer AvKARE, application ANDA072708), returned on 2026-11-09. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260121.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      02054d47d2e219137166fc69012547112cfc3ee1d6b50c0298a6163ea9658e9e
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    7. Supports MeSH scope note for descriptor D014665 (Vasodilator Agents)

      Dataset · U.S. National Library of Medicine · Edition MeSH linked-data record of the preferred concept M0022559 of descriptor D014665, fetched 2026-11-09. The scope note is on this concept record, not on the descriptor record. · MeSH: M0022559

      Locator
      scopeNote.@value
      How it applies
      MeSH scope note: what vasodilator agents are.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      c3651b01270284b23f245ca88fd1185739a299f3cecd5a0f220667884e135043
      Reuse basis
      The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-11-09 and may not reflect the most current data. The raw bytes are committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:direct-vasodilators-hydralazine-minoxidil
Content hash
e7eebdace104acaa41f548a3d6498183e959a17d1c76174d3fa7dca63899f0aa